(Q36747692)

16 August 2017

1 reference

title

Triple-negative breast cancer: therapeutic options (English)

1 reference

triple-negative breast cancer

16 August 2017

1 reference

1 reference

Susan Cleator

1 reference

16 August 2017

Wolfgang Heller

series ordinal

1 reference

16 August 2017

R Charles Coombes

series ordinal

1 reference

16 August 2017

publication date

1 March 2007

1 reference

Lancet Oncology Commission

16 August 2017

published in

1 reference

16 August 2017

1 reference

16 August 2017

1 reference

16 August 2017

page(s)

235-244

1 reference

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Effect of screening and adjuvant therapy on mortality from breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Repeated observation of breast tumor subtypes in independent gene expression data sets

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Gene expression profiling predicts clinical outcome of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Centrally necrotizing carcinomas of the breast: a distinct histologic subtype with aggressive clinical behavior

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Expression of luminal and basal cytokeratins in human breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Steroid hormone receptor status of mouse mammary stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Basal-like breast carcinomas: clinical outcome and response to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

The molecular portraits of breast tumors are conserved across microarray platforms

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Mutations in human breast cancer: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

MYC is amplified in BRCA1-associated breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Hallmarks of 'BRCAness' in sporadic cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Familial invasive breast cancers: worse outcome related to BRCA1 mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

p53 mutations in BRCA1-associated familial breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

BRCA1 mutations in primary breast and ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Basal-like breast cancer and the BRCA1 phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

The role of BRCA1 in the cellular response to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Targeting the DNA repair defect of BRCA tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Choices--and uncertainties--for women with BRCA mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Exploiting the DNA Repair Defect in BRCA Mutant Cells in the Design of New Therapeutic Strategies for Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Proliferation marker Ki-67 in early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

p53-independent apoptosis induced by paclitaxel through an indirect mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Platinum-based chemotherapy in metastatic breast cancer: the Leicester (U.K.) experience.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Treating cancer by blocking cell signals

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Epidermal growth factor receptor targeting in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Treatment for advanced tumors: SRC reclaims center stage

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970074-8

7 January 2021

10.1016/S1470-2045(07)70074-8

Identifiers

DOI

1 reference

release_unkeynwqjvcivgbbogjxdw5454

16 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/unkeynwqjvcivgbbogjxdw5454

24 November 2022

mapped directly with Wikidata item

1 reference